Ezetimibe reduces urinary albumin excretion in hypercholesterolaemic type 2 diabetes patients with microalbuminuria.

Abstract

OBJECTIVE:

This study investigated the effects of ezetimibe, an inhibitor of intestinal cholesterol absorption, on early phase diabetic nephropathy.

METHODS:

A total of 32 hypercholesterolaemic type 2 diabetes patients with microalbuminuria, defined as a urinary albumin excretion (UAE) 30 but < 300 mg/g creatinine, were enrolled. Various clinical and laboratory parameters were determined at baseline and after 6 months of treatment with 10 mg/day ezetimibe.

RESULTS:

Ezetimibe treatment significantly decreased glycated haemoglobin (HbA(1c)), low-density lipoprotein-cholesterol (LDL-C), triglycerides and UAE, and significantly increased high-density lipoprotein-cholesterol and albumin. It also decreased the serum level of monocyte chemoattractant protein-1 (MCP-1), but this difference was not statistically significant. Univariate analyses showed a correlation between UAE and body mass index, systolic and diastolic blood pressures, HbA(1c), LDL-C, estimated glomerular filtration rate (inverse), creatinine and MCP-1. Since these parameters may be closely correlated with each other, multiple stepwise regression analysis was performed and demonstrated that HbA(1c) and MCP-1 were independent determinants of UAE.

CONCLUSIONS:

Ezetimibe may be a promising therapeutic strategy for improving albumin excretion, partly through its anti-inflammatory properties, and for reducing LDL-C in hypercholesterolaemic type 2 diabetes patients with microalbuminuria.

• Authors: T Nakamura, E Sato, M Amaha, Y Kawagoe, S Maeda, H Inoue, S I Yamagishi
• Journal: The Journal of international medical research (J Int Med Res) Vol. 40 Issue 2 Pg. 798-803 ( 2012) ISSN: 1473-2300 [Electronic] England
• PMID: 22613445 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Albumins
• Azetidines
• CCL2 protein, human
• Chemokine CCL2
• Cholesterol, LDL
• Glycated Hemoglobin A
• Triglycerides
• Ezetimibe

Topics

• Albumins (analysis)
• Albuminuria (drug therapy)
• Azetidines (pharmacology, therapeutic use)
• Blood Pressure
• Body Mass Index
• Chemokine CCL2 (blood)
• Cholesterol, LDL (blood)
• Diabetes Mellitus, Type 2 (complications, drug therapy)
• Diabetic Nephropathies (complications, drug therapy)
• Ezetimibe
• Female
• Glycated Hemoglobin (analysis)
• Humans
• Hypercholesterolemia (complications, drug therapy)
• Male
• Middle Aged
• Triglycerides (blood)